Axsome Therapeutics Inc (OQ:AXSM)

Business Focus: Bio Therapeutic Drugs

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
See Regulatory Filings on SEC
Company Contact
Address: 200 Broadway 3rd Floor
NEW YORK NY 10038-2542
Tel: N/A
Website: axsome.com
IR: See website
<
Key People
Herriot Tabuteau
Chairman of the Board, President, Chief Executive Officer
Nick Pizzie
Chief Financial Officer
Joseph Debrah-Affu
Director of Finance, Interim Principal Accounting Officer
Mark Jacobson
Senior Vice President- Operations, Secretary
Cedric O'Gorman
Senior Vice President- Clinical Development and Medical Affairs
Robert Niecestro
Vice President- Clinical and Regulatory
David C. Marek
Chief Commercial Officer
   
Business Overview
Axsome Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapies for the management of central nervous system (CNS) disorders, including pain. It operates in the business of developing novel therapies for the management of CNS disorders segment. Its product candidate, AXS-02 (disodium zoledronate tetrahydrate), is an oral, targeted, non opioid therapeutic for chronic pain. It is developing AXS 02 for the treatment of pain in over three conditions, such as complex regional pain syndrome (CRPS); knee osteoarthritis (OA) associated with bone marrow lesions (BMLs), and chronic low back pain (CLBP), associated with type I, or mixed type I and type II Modic changes (MCs). Its product candidate, AXS 05, is a fixed dose combination of dextromethorphan (DM) and bupropion. It is developing AXS 05 for the treatment of over two conditions, such as treatment resistant depression (TRD), and agitation in patients with Alzheimer's disease (AD).
Financial Overview
For the six months ended 30 June 2019, Axsome Therapeutics Inc revenues was not reported. Net loss increased 86% to $24.4M. Higher net loss reflects Research and development - Other increase of 81% to $18.2M (expense), Change in fair value of warrant liabilit decrease from $2.7M (income) to $0K, Stock-based Compensation in SGA increase from $788K to $1.8M (expense).
Employees: 37 as of Aug 2, 2019
Reporting Currency: U.S. Dollars
Enterprise value: $821.13M as of Jun 30, 2019
Annual revenue (TTM): $0.00M as of Jun 30, 2019
EBITDA (TTM): -$41.52M as of Jun 30, 2019
Net annual income (TTM): -$42.28M as of Jun 30, 2019
Free cash flow (TTM): -$33.91M as of Jun 30, 2019
Net Debt Last Fiscal Year: N/A
Shares outstanding: 34,330,441 as of Aug 2, 2019
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization